表紙
市場調査レポート

脳梗塞:パイプライン製品の分析

Cerebral Infarction (Brain Infarction) - Pipeline Review, H2 2015

発行 Global Markets Direct 商品コード 257808
出版日 ページ情報 英文 36 Pages
即納可能
価格
本日の銀行送金レート: 1USD=102.12円で換算しております。
Back to Top
脳梗塞:パイプライン製品の分析 Cerebral Infarction (Brain Infarction) - Pipeline Review, H2 2015
出版日: 2015年10月28日 ページ情報: 英文 36 Pages
概要

脳梗塞は脳内部の血管が閉塞され、血流が遮断されることで発症します。その発症原因は様々で、血栓・血餅の形成や塞栓症、脳静脈洞血栓症などが含まれています。主な症状として、顔面や他の身体部位における筋力低下や、刺痛・しびれ、言語能力・会話理解力の低下、意識混濁、記憶障害などが挙げられます。

当レポートでは、世界各国での脳梗塞治療用のパイプライン製品の開発状況について分析し、製品開発・上市の最新動向や、治験の各段階にある製品の一覧、主要企業のプロファイル、主な薬剤の概要、最新の業界動向などの情報をお届けします。

目次

イントロダクション

  • 分析範囲

脳梗塞の概要

治療薬の開発

  • 脳梗塞向けパイプライン製品:概要
  • 脳梗塞向けパイプライン製品:比較分析

各企業で開発中の脳梗塞治療薬

大学/研究機関で研究中の脳梗塞治療薬

パイプライン製品の概略

  • 治験段階の製品
  • 初期段階の製品

脳梗塞治療薬:開発中の製品の一覧(企業別)

脳梗塞治療薬:研究中の製品の一覧(大学/研究機関別)

脳梗塞治療薬の開発に従事している企業

  • Johnson & Johnson
  • CIMAB S.A.
  • 新日本科学
  • Aprogen, Inc.

脳梗塞:治療薬の評価

  • 単剤治療薬の場合
  • 標的別
  • 作用機序別
  • 投与方法別
  • 分子の種類別

薬剤のプロファイル

  • 自家骨髄由来の間葉系幹細胞
    • 製品概要
    • 機能メカニズム
    • 研究開発(R&D)の進展状況
  • エポエチンα
  • CNTO-0007
  • AP-102
  • 脳梗塞向け医薬品
  • 抗HMGB1モノクローナル抗体

脳梗塞治療薬:開発が休止状態の製品

脳梗塞治療薬:開発が中止された製品

脳梗塞関連製品の開発のマイルストーン

  • 注目すべき最新動向・プレスリリース(全4件)

付録

図表一覧

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC7273IDB

Summary

Global Markets Direct's, 'Cerebral Infarction (Brain Infarction) - Pipeline Review, H2 2015', provides an overview of the Cerebral Infarction (Brain Infarction)'s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Cerebral Infarction (Brain Infarction), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cerebral Infarction (Brain Infarction) and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Cerebral Infarction (Brain Infarction)
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Cerebral Infarction (Brain Infarction) and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Cerebral Infarction (Brain Infarction) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Cerebral Infarction (Brain Infarction) pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products

Reasons to buy

  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Cerebral Infarction (Brain Infarction)
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Cerebral Infarction (Brain Infarction) pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Cerebral Infarction (Brain Infarction) Overview
  • Therapeutics Development
    • Pipeline Products for Cerebral Infarction (Brain Infarction) - Overview
    • Pipeline Products for Cerebral Infarction (Brain Infarction) - Comparative Analysis
  • Cerebral Infarction (Brain Infarction) - Therapeutics under Development by Companies
  • Cerebral Infarction (Brain Infarction) - Therapeutics under Investigation by Universities/Institutes
  • Cerebral Infarction (Brain Infarction) - Pipeline Products Glance
    • Clinical Stage Products
    • Early Stage Products
  • Cerebral Infarction (Brain Infarction) - Products under Development by Companies
  • Cerebral Infarction (Brain Infarction) - Products under Investigation by Universities/Institutes
  • Cerebral Infarction (Brain Infarction) - Companies Involved in Therapeutics Development
    • Johnson & Johnson
    • R-Tech Ueno, Ltd.
    • Shin Nippon Biomedical Laboratories, Ltd.
  • Cerebral Infarction (Brain Infarction) - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • CNTO-0007 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • epoetin alfa - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Monoclonal Antibody to Inhibit HMGB1 for Brain Infarction - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Peptide for Cerebral Infarction - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • RTU-009 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Cerebral Infarction (Brain Infarction) - Recent Pipeline Updates
  • Cerebral Infarction (Brain Infarction) - Dormant Projects
  • Cerebral Infarction (Brain Infarction) - Dormant Projects
  • Cerebral Infarction (Brain Infarction) - Discontinued Products
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Cerebral Infarction (Brain Infarction), H2 2015
  • Number of Products under Development for Cerebral Infarction (Brain Infarction) - Comparative Analysis, H2 2015
  • Number of Products under Development by Companies, H2 2015
  • Number of Products under Investigation by Universities/Institutes, H2 2015
  • Comparative Analysis by Clinical Stage Development, H2 2015
  • Comparative Analysis by Early Stage Development, H2 2015
  • Products under Development by Companies, H2 2015
  • Products under Investigation by Universities/Institutes, H2 2015
  • Cerebral Infarction (Brain Infarction) - Pipeline by Johnson & Johnson, H2 2015
  • Cerebral Infarction (Brain Infarction) - Pipeline by R-Tech Ueno, Ltd., H2 2015
  • Cerebral Infarction (Brain Infarction) - Pipeline by Shin Nippon Biomedical Laboratories, Ltd., H2 2015
  • Assessment by Monotherapy Products, H2 2015
  • Number of Products by Stage and Target, H2 2015
  • Number of Products by Stage and Mechanism of Action, H2 2015
  • Number of Products by Stage and Route of Administration, H2 2015
  • Number of Products by Stage and Molecule Type, H2 2015
  • Cerebral Infarction (Brain Infarction) Therapeutics - Recent Pipeline Updates, H2 2015
  • Cerebral Infarction (Brain Infarction) - Dormant Projects, H2 2015
  • Cerebral Infarction (Brain Infarction) - Discontinued Products, H2 2015

List of Figures

  • Number of Products under Development for Cerebral Infarction (Brain Infarction), H2 2015
  • Number of Products under Development for Cerebral Infarction (Brain Infarction) - Comparative Analysis, H2 2015
  • Number of Products under Development by Companies, H2 2015
  • Number of Products under Investigation by Universities/Institutes, H2 2015
  • Comparative Analysis by Clinical Stage Development, H2 2015
  • Comparative Analysis by Early Stage Products, H2 2015
  • Assessment by Monotherapy Products, H2 2015
  • Number of Products by Top 10 Targets, H2 2015
  • Number of Products by Stage and Top 10 Targets, H2 2015
  • Number of Products by Top 10 Mechanism of Actions, H2 2015
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015
  • Number of Products by Top 10 Routes of Administration, H2 2015
  • Number of Products by Stage and Top 10 Routes of Administration, H2 2015
  • Number of Products by Top 10 Molecule Types, H2 2015
  • Number of Products by Stage and Top 10 Molecule Types, H2 2015
Back to Top